CBFβ-MYH11/ABL ratios, as evaluated by real-time RT-PCR.

One hundred twenty-five samples were taken from 21 patients with inv(16) AML during or after treatment in the absence of subsequent relapse (Group A), at any time during follow-up before relapse (Group B), or at the time of diagnosis or relapse (Group C). Differences among the 3 groups were all highly significant (P < .0001), as determined by the Kruskal-Wallis test. When values were lower than 0.12%, no subsequent relapse was recorded, but when values were greater than 0.25%, relapse always occurred. Values fell within the intermediate gray zone for 6 samples. Median values of each group (—).